Advancing Prostate Cancer Survivorship through Transatlantic Consortium Science: The iCCaRE Initiative
Black men experience the highest global burden of prostate cancer
Black/African American populations, globally, bear the greatest prostate cancer burden compared with other racial/ethnic groups. Addressing prostate cancer disparities in Black men is complex, requiring a patient‑centered, community‑centric, and comprehensive approach. This study integrates Inclusive Cancer Care Research Equity (iCCaRE) Consortium findings and broader literature to address unmet needs in survivorship care. The iCCaRE Consortium implemented five complementary pilot studies using mixed‑methods designs, including feasibility trials, qualitative research, and observational analyses across the United States and sub‑Saharan Africa. Collectively, projects addressed multilevel determinants, including social, behavioral, and biological drivers of disparities. Project 1 implemented a Virtual Realty Assistant across clinical and community settings, with ongoing evaluation in pragmatic trials. Project 2 showed strong patient preference for home‑based cancer care. Project 3 demonstrated trends toward improved health‑related quality of life. Project 4 identified key themes influencing survivorship experiences. Project 5 identified biological mechanisms linking stress, immune modulation, and symptom burden. The iCCaRE pilot projects demonstrate the feasibility and early impact of a consortium‑based, transdisciplinary approach to addressing prostate cancer disparities in Black men. These findings highlight the importance of integrating patient‑centered interventions, community engagement, and biological insights to inform scalable strategies aimed at improving survivorship outcomes and advancing health equity.
Black men experience the highest global burden of prostate cancer
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience